Novavax likely won't file for emergency use authorization with the FDA for its COVID-19 vaccine until June, four people familiar with the matter told The Washington Post.
Novavax's vaccine was shown to be about 90 percent effective in a 15,000-person trial in the U.K. While it's unclear how widespread its use would be in the U.S. if authorized by the FDA, it could be widely used globally, the Post reported May 10. It's an easy-to-store vaccine and could help bolster global COVID-19 vaccine supplies.
But Novavax's North American trial has been delayed several times. It didn't begin until the end of December because of manufacturing issues, according to the Post.
Novavax's president of research and development, Gregory Glenn, said in February that results from the trial were expected at the beginning of the second quarter, which started April 1. Now, results aren't expected until the end of May, the Post reported.
Novavax set a goal of making 2 billion vaccine doses per year. More than 1 billion doses of its vaccine have been pledged to Covax, the initiative co-led by the World Health Organization to ensure equitable COVID-19 vaccine distribution across the globe.
Read the full article here.